Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study

Summary Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2016-11, Vol.175 (3), p.462-466
Hauptverfasser:	Thompson, Philip A., Lévy, Vincent, Tam, Constantine S., Al Nawakil, Chadi, Goudot, François‐Xavier, Quinquenel, Anne, Ysebaert, Loic, Michallet, Anne‐Sophie, Dilhuydy, Marie‐Sarah, Van Den Neste, Eric, Dupuis, Jehan, Keating, Michael J., Meune, Christophe, Cymbalista, Florence
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use atrial fibrillation Atrial Fibrillation - diagnosis Atrial Fibrillation - etiology Atrial Fibrillation - therapy chronic lymphocytic leukaemia Disease Management Female Hemorrhage - diagnosis Hemorrhage - etiology Hemorrhage - therapy Humans ibrutinib Leukemia, Lymphocytic, Chronic, B-Cell - complications Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Male Middle Aged Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!